Relationship between anti-CCP antibodies and oxidant and anti-oxidant activity in patients with rheumatoid arthritis

International Journal of Medical Sciences

Volumn 8, Issue 2, 2011, Pages 139-147

  Ediz, Levent ^a   Hiz, Ozcan ^a   Ozkol, Halil ^a   Gulcu, Elif ^a   Toprak, Murat ^a   Ceylan, Mehmet Fethi ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Anti CCP antibody; Malondialdehyde; Myeloperoxidase; Oxidative stress; Rheumatoid arthritis; Synovial fluid

Indexed keywords

AUTOANTIBODY; CATALASE; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MYELOPEROXIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR;

ADULT; ARTICLE; BLOOD; CIRCULATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; RHEUMATOID ARTHRITIS; SERUM; SYNOVIAL FLUID;

EID: 79951800274     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.8.139     Document Type: Article

References (36)

1. Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Sym-mons D, Barton A. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007;56:2929-2935.
2. Cuzzocrea S. Role of nitric oxide and reactive oxygen species in arthritis. Curr Pharm Des 2006;12:3551-3370.
3. Hagfors L, Leanderson P, Skoldstam L, Andersson J, Johansson G. Antioxidant intake, plasma antioxidants and oxidative stress in a randomized, controlled, parallel, Mediterranean dietary intervention study on patients with rheumatoid arthritis. Nutr J 2003;2:5.
4. Ostrakhovitch EA, Afanas'ev IB. Oxidative stress in rheuma-toid arthritis leukocytes: suppression by rutin and other anti-oxidants and chelators. Biochem Pharmacol 2001; 62:743-746.
5. Gambhir JK, Lali P, Jain AK. Correlation between blood anti-oxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem 1997;30:351-155.
6. Kiziltunc AC, Ogalgil S, Cerrahoglu L. Carnithine and antiox-idants levels in patients with rheumatoid arthritis. Scand J Rheumatol 1998;27:441-445.
7. Cerhan JR, Saag KG, Merlino LA, Mikuls TR, Criswell LA. Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol 2003;157:345-354.
8. Paredes S, Girona J, Hurt-Camejo E, Vallve JC, Olive S, Heras M, Benito P, Masana L. Antioxidant vitamins and lipid peroxi- dation in patients with rheumatoid arthritis: association with inflammatory markers. J Rheumatol 2002; 29:2271-2277.
9. Mulherin DM, Thurnham DI, Situnayake RD. Glutathione reductase activity, riboflavin status, and disease activity in rheumatoid arthritis. Ann Rheum Dis 1996;55:837-840.
10. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B et al. Longitudinal analysis of citrullinated protein/peptide anti-bodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-1749.
11. Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010;62:44-52.
12. Silveira IG, Burlingame RW, von Mühlen CA, Bender AL, Staub HL. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 2007;26:1883-1889.
13. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-973.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
15. Placer ZA, Cushman L, Johnson BC. Estimation of products of lipid peroxidation (malonyl dialdehyde) in biological fluids. Anal Biochem 1966;16:359-364.
16. Aebi H. Catalase. In: Bergmeyer HU, ed. Methods of enzymatic analysis, 3rd edn. New York: Academic Press. 1974: 673- 677.
17. Matkovics B, Szabo L, Varga I.S. Determination of enzyme ac-tivities in lipid peroxidation and glutathione pathways. Labor-atoriumi Diagnosztika 1988;15:248-249.
18. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Meas-urement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. Journal of Investigative Der-matology 1982;78:206-209.
19. Wolfe F. The Many Myths of Erythrocyte Sedimentation Rate and C-Reactive Protein. J Rheumatol 2009;36:1568-1569.
20. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheu-matoid arthritis. Arthritis Rheum 2003;48:2741-2749.
21. Vossenaar ER, Nijenhuis S, Helsen MM, van der Heijden A, Senshu T et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003;48:2489-2500.
22. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003;25:1106-1118.
23. Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A. Etanercept reduces the oxidative stress marker levels in pa-tients with rheumatoid arthritis. Rheumatol Int 2008;28:245-251.
24. Atzeni F, Sarzi-Puttini P, Dell Acqua D, de Portu S, Cecchini G et al. Adalimumab clinical efficacy is associated with rheuma-toid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006;8:R3.
25. Biemond P, Swaak AJ, Koster JF. Protective factors against oxygen free radicals and hydrogen peroxide in rheumatoid ar-thritis synovial fluid. Arthritis Rheum 1984;27:760-765.
26. De Leo ME, Tranghese A, Passantino M, Mordente A, Lizzio MM et al. Manganese superoxide dismutase, glutathione pe-roxidase, and total radical trapping antioxidant capacity in ac-tive rheumatoid arthritis. J Rheumatol 2002;29:2245-2246.
27. Taysi S, Polat F, Gul M, Sari RA, Bakan E. Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int 2002;21:200-204.
28. Cimen MY, Cimen OB, Kacmaz M, Ozturk HS, Yorgancioglu R, Durak I. Oxidant/antioxidant status of the erythrocytes from patients with rheumatoid arthritis. Clin Rheumatol 2000;19:275-277.
29. Bandt MD, Grossin M, Driss F, Pincemail J, Babin-Chevaye C, Pasquier C. Vitamin E uncouples joint destruction and clinical inflammation in a transgenic mouse model of rheumatoid ar-thritis. Arthritis Rheum 2002;46:522-532.
30. Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthri-tis. Arthritis Res Ther 2004;6:265-278.
31. Dai L, Lamb DJ, Leake DS, Kus ML, Jones HW et al. Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients. Free Radic Res 2000;32:479-486.
32. Michiels C, Raes M, Toussaint O, Remacle J. Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med 1994;17:235-248.
33. Kamanli A, Naziroglu M, Aydilek N, Hacievliyagil C. Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochem Funct 2004;22:53-57.
34. Olivieri O, Girelli D, Trevisan MT, Bassi A, Zorzan P et al. Red blood cell susceptibility to lipid peroxidation, membrane lipid composition and antioxidant enzymes in patients with rheu-matoid arthritis. J Rheumatol 1991;18:1263- 1264.
35. van der Veen BS, de Winther MP, Heeringa P. Myeloperoxi-dase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal 2009;11:2899-2937.
36. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485-3494.